PMID- 27802290
OWN - NLM
STAT- MEDLINE
DCOM- 20170621
LR  - 20181113
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 11
IP  - 11
DP  - 2016
TI  - Naturally Occurring Autoantibodies against Tau Protein Are Reduced in Parkinson's 
      Disease Dementia.
PG  - e0164953
LID - 10.1371/journal.pone.0164953 [doi]
LID - e0164953
AB  - BACKGROUND AND OBJECTIVE: Altered levels of naturally occurring autoantibodies 
      (nAbs) against disease-associated neuronal proteins have been reported for 
      neurodegenerative diseases, such as Alzheimer's (AD) and Parkinson's disease 
      (PD). Recent histopathologic studies suggest a contribution of both Lewy body- 
      and AD-related pathology to Parkinson's disease dementia (PDD). Therefore, we 
      explored nAbs against alpha-synuclein (alphaS), tau and beta-amyloid (Abeta) in PDD 
      compared to cognitively normal PD patients. MATERIALS AND METHODS: We established 
      three different ELISAs to quantify the nAbs-tau, nAbs-alphaS, and nAbs-Abeta levels and 
      avidity towards their specific antigen in serum samples of 18 non-demented (PDND) 
      and 18 demented PD patients (PDD), which were taken from an ongoing multi-center 
      cohort study (DEMPARK/LANDSCAPE). RESULTS: PDD patients had significantly 
      decreased nAbs-tau serum levels compared to PDND patients (p = 0.007), whereas 
      the serum titers of nAbs-alphaS and nAbs-Abeta were unchanged. For all three nAbs, no 
      significant differences in avidity were found between PDD and PDND cohorts. 
      However, within both patient groups, nAbs-tau showed lowest avidity to their 
      antigen, followed by nAbs-alphaS, and nAbs-Abeta. Though, due to a high interassay 
      coefficient of variability and the exclusion of many samples below the limit of 
      detection, conclusions for nAbs-Abeta are only conditionally possible. CONCLUSION: 
      We detected a significantly decreased nAbs-tau serum level in PDD patients, 
      indicating a potential linkage between nAbs-tau serum titer and cognitive 
      deficits in PD. Thus, further investigation in larger samples is justified to 
      confirm our findings.
FAU - Kronimus, Yannick
AU  - Kronimus Y
AD  - Department of Neurology, Philipps-University, Marburg, Germany.
FAU - Albus, Alexandra
AU  - Albus A
AD  - Department of Neurology, Philipps-University, Marburg, Germany.
FAU - Balzer-Geldsetzer, Monika
AU  - Balzer-Geldsetzer M
AD  - Department of Neurology, Philipps-University, Marburg, Germany.
FAU - Straub, Sarah
AU  - Straub S
AD  - Department of Neurology, University of Ulm, Ulm, Germany.
FAU - Semler, Elisa
AU  - Semler E
AD  - Department of Neurology, University of Ulm, Ulm, Germany.
FAU - Otto, Markus
AU  - Otto M
AD  - Department of Neurology, University of Ulm, Ulm, Germany.
FAU - Klotsche, Jens
AU  - Klotsche J
AD  - German Rheumatism Research Centre Berlin, a Leibniz Institute, Berlin, Germany.
AD  - Charite University Medicine Berlin, Institute for Social Medicine, Epidemiology 
      and Health Economics, Berlin, Germany.
FAU - Dodel, Richard
AU  - Dodel R
AD  - Department of Neurology, Philipps-University, Marburg, Germany.
AD  - Department of Neuro-geriatrics, University Clinic, Essen, Germany.
CN  - LANDSCAPE Consortium
FAU - Mengel, David
AU  - Mengel D
AD  - Department of Neurology, Philipps-University, Marburg, Germany.
LA  - eng
PT  - Journal Article
DEP - 20161101
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - 0 (Amyloid beta-Peptides)
RN  - 0 (Autoantibodies)
RN  - 0 (alpha-Synuclein)
RN  - 0 (tau Proteins)
SB  - IM
MH  - Amyloid beta-Peptides/immunology
MH  - Autoantibodies/*immunology
MH  - Cognition Disorders/immunology
MH  - Cohort Studies
MH  - Dementia/*immunology
MH  - Female
MH  - Humans
MH  - Male
MH  - Parkinson Disease/*immunology
MH  - alpha-Synuclein/immunology
MH  - tau Proteins/*immunology
PMC - PMC5089716
COIS- RD is an investigator on patents on naturally occurring autoantibodies which are 
      held by the Philipps-University of Marburg. There are no further patents, 
      products in development or marketed products with relevance to the present study 
      to declare. This does not alter the authors' adherence to all the PLOS ONE 
      policies on sharing data and materials.
EDAT- 2016/11/02 06:00
MHDA- 2017/06/22 06:00
PMCR- 2016/11/01
CRDT- 2016/11/02 06:00
PHST- 2016/06/24 00:00 [received]
PHST- 2016/10/04 00:00 [accepted]
PHST- 2016/11/02 06:00 [pubmed]
PHST- 2017/06/22 06:00 [medline]
PHST- 2016/11/02 06:00 [entrez]
PHST- 2016/11/01 00:00 [pmc-release]
AID - PONE-D-16-25457 [pii]
AID - 10.1371/journal.pone.0164953 [doi]
PST - epublish
SO  - PLoS One. 2016 Nov 1;11(11):e0164953. doi: 10.1371/journal.pone.0164953. 
      eCollection 2016.